Evidence map›Paper›PMID 39628301›Full record

ArticleCancer science2025

The impact of BTK knockdown on lung adenocarcinoma growth and immune response.

Jilan Huang, Yufan Yuan, Linghong Guo, Guojin Xia, Yan Chen, Qi Chen, Min Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jilan HuangDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yufan YuanDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Linghong GuoDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Guojin XiaDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.ORCID https://orcid.org/0009-0005-8428-8236
Yan ChenDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Qi ChenDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Min WangDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Funding

Clinical Research Center For Medical Imaging In Jiangxi Province 20223BCG74001National Natural Science Foundation of China 81760307
6 · The paper itself

Abstract

This study explores the molecular role of the BTK gene in lung adenocarcinoma (LUAD) progression and patient prognosis. Using a radiomics model based on BTK expression and PET-CT data analyzed through DeeplabV3, alongside transcriptomic and clinical data from TCGA, we established a strong predictive relationship between BTK levels and LUAD outcomes. Our findings demonstrate that low BTK expression is linked to poorer prognoses. Experimental models, including cell lines and in vivo mouse studies, revealed that BTK deficiency leads to increased LUAD cell proliferation, invasion, and metastasis. Furthermore, in vivo models indicated that BTK knockdown results in enhanced tumor growth and diminished CD8+ T cell activity. These results suggest that BTK plays a crucial role in modulating LUAD progression and the tumor immune environment, highlighting its potential as a therapeutic target.

Indexed as

Adenocarcinoma of LungAgammaglobulinaemia Tyrosine KinaseLung NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMaleMicePositron Emission Tomography Computed TomographyPrognosisTumor MicroenvironmentAgammaglobulinaemia Tyrosine KinaseBTK protein, humanBTK geneCD8+ T cellslung adenocarcinomaPET‐CTradiomics modeltranscriptomics

Identifiers

PMID39628301
PMCPMC12127088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.